We are live on
!
Find out more
ACM
Atika Capital Management Portfolio holdings
AUM
$796M
1-Year Est. Return
167.57%
This Fund
S&P 500
This Quarter
Est. Return
+18.09%
1 Year Est. Return
+167.57%
3 Year Est. Return
+553.47%
5 Year Est. Return
+1,283.26%
10 Year Est. Return
+44,203.78%
AUM
$222M
AUM Growth
+$72.3M
(+48%)
Cap. Flow
+$53.1M
Cap. Flow
% of AUM
23.89%
Top 10 Holdings %
Top 10 Hldgs %
37.08%
Holding
85
New
24
Increased
35
Reduced
7
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Netflix
NFLX
|
+$10.4M |
| 2 |
Martin Marietta Materials
MLM
|
+$4.71M |
| 3 |
ADPT
Adeptus Health Inc
ADPT
|
+$4.2M |
| 4 |
AbbVie
ABBV
|
+$4.04M |
| 5 |
SS&C Technologies
SSNC
|
+$3.99M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advance Auto Parts
AAP
|
+$4.49M |
| 2 |
OCR
OMNICARE INC
OCR
|
+$4.01M |
| 3 |
Edwards Lifesciences
EW
|
+$3.28M |
| 4 |
TWTR
Twitter, Inc.
TWTR
|
+$3.1M |
| 5 |
GRUB
Just Eat Takeaway.com N.V. American Depositary Shares
GRUB
|
+$2.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 39.19% |
| 2 | Communication Services | 11.73% |
| 3 | Consumer Discretionary | 10.64% |
| 4 | Industrials | 9.59% |
| 5 | Materials | 5.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ESPR
51
CALL
DELISTED
Esperion Therapeutics
ESPR
| $1.5M | 0.67% |
+18,300
| New | +$1.79M |
|
52
Caesarstone
CSTE
$72.3M
| $1.44M | 0.65% |
21,000
-14,000
| -40% | -$865K |
|
53
Corpay
CPAY
$25B
| $1.42M | 0.64% |
9,100
+600
| +7% | +$94.1K |
|
54
HealthEquity
HQY
$8.41B
| $1.31M | 0.59% |
41,000
+15,400
| +60% | +$413K |
|
|
XENT
55
DELISTED
Intersect ENT, Inc
XENT
| $1.29M | 0.58% |
45,200
+7,200
| +19% | +$189K |
|
|
CELG
56
PUT
DELISTED
Celgene Corp
CELG
| $1.22M | 0.55% |
+10,500
| New | +$1.2M |
|
|
BLUE
57
PUT
DELISTED
bluebird bio
BLUE
| $1.21M | 0.55% |
+556
| New | +$1.13M |
|
58
Ultragenyx Pharmaceutical
RARE
$2.45B
| $1.06M | 0.48% |
+10,400
| New | +$808K |
|
|
PARA
59
CALL
DELISTED
Paramount Global Class B
PARA
| $910K | 0.41% |
16,400
+3,100
| +23% | +$187K |
|
|
KITE
60
PUT
DELISTED
Kite Pharma, Inc.
KITE
| $878K | 0.4% |
+14,400
| New | +$822K |
|
61
AMN Healthcare
AMN
$1.3B
| $805K | 0.36% |
+25,500
| New | +$666K |
|
62
CALL
Acadia Pharmaceuticals
ACAD
$4.43B
| $711K | 0.32% |
17,000
-4,200
| -20% | -$163K |
|
|
FIT
63
DELISTED
Fitbit, Inc. Class A common stock
FIT
| $688K | 0.31% |
+18,000
| New | +$632K |
|
64
Agios Pharmaceuticals
AGIO
$1.79B
| $662K | 0.3% |
5,950
+950
| +19% | +$102K |
|
|
ESPR
65
DELISTED
Esperion Therapeutics
ESPR
| $654K | 0.29% |
8,000
-19,500
| -71% | -$1.91M |
|
|
RCPT
66
CALL
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $266K | 0.12% |
+1,400
| New | +$231K |
|
|
67
Advance Auto Parts
AAP
$3.35B
| – | – |
-30,000
| Closed | -$4.49M |
|
|
68
Acadia Pharmaceuticals
ACAD
$4.43B
| – | – |
-35,000
| Closed | -$1.35M |
|
69
Allegion
ALLE
$13.4B
| – | – |
-32,000
| Closed | -$1.96M |
|
70
Bausch Health
BHC
$2.58B
| – | – |
-6,000
| Closed | -$1.19M |
|
|
71
Edwards Lifesciences
EW
$49.6B
| – | – |
-138,000
| Closed | -$3.28M |
|
72
PUT
GameStop
GME
$9.75B
| – | – |
-175,200
| Closed | -$1.66M |
|
73
Incyte
INCY
$24.2B
| – | – |
-20,000
| Closed | -$1.83M |
|
|
HAPN
74
Happen Inc
HAPN
$2.21B
| – | – |
-13,000
| Closed | -$1.28M |
|
75
Teva Pharmaceuticals
TEVA
$40.8B
| – | – |
-38,000
| Closed | -$2.37M |
|
Similar funds
AGA
RIM
ACM
CAM
LSA
GWA
HP
Atika Capital Management's Q2 2015 Portfolio in Review
As of Q2 2015, Atika Capital Management held 85 positions worth $222M, up 48% from $150M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Atika Capital Management deployed $53.1M of net new capital in Q2 2015, opening 24 new positions and adding to 35 existing holdings. Its largest new stake was Netflix: 1,242,500 shares worth $11.7M.
By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 40% a quarter earlier, followed by Communication Services and Consumer Discretionary.
On the sell side, the largest reduction was Esperion Therapeutics, an estimated $1.91M trimmed.
- Atika Capital Management's largest Q2 2015 buy was Netflix: 1,242,500 shares worth $11.7M.
- Atika Capital Management added most to Martin Marietta Materials in Q2 2015, an estimated $4.71M increase.
- Atika Capital Management's biggest Q2 2015 reduction was Esperion Therapeutics, cutting an estimated $1.91M.
- Atika Capital Management fully exited Advance Auto Parts in Q2 2015, selling an estimated $4.49M.
- Atika Capital Management's ten largest holdings make up 37% of its $222M portfolio in Q2 2015.
- Atika Capital Management opened 24 new positions and closed 19 in Q2 2015.
- Atika Capital Management's portfolio value rose 48% quarter-over-quarter to $222M.
Based on Atika Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.